Manufacturing

Review of SUT Adoption in Biopharma Manufacturing

The evolution of therapeutic modalities drives the adoption of single-use technologies.

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Automating the Future of Fill/Finish

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

Leap Year

January 03, 2024

Revolutionary therapies restructure pharmaceutical manufacturing.

Bridging Gaps and Investing in Change

January 03, 2024

European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.

New Therapies Cry Out for New Skills

January 03, 2024

There are positive indications for future growth.

Navigating Trends in Secondary Packaging

January 03, 2024

Designers adopt value-added features, different materials, and enhanced coding technologies.

Replay Signs Exclusive Licensing Agreements with NIH and Miltenyi Biotec for Cell Therapy Development and Manufacturing

December 29, 2023

Through Syena, its oncology-focused product company, Replay will develop and manufacture T-cell receptor and natural killer cell therapies with the NIH and Miltenyi Biotec.

Körber and Franz Ziel Tighten Ties

December 28, 2023

Is increasing molecular diversity pushing manufacturing ecosystem consolidation toward turnkey solutions?

Tome brings $213 Million to the Programmable Genome Editing Party

December 28, 2023

Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.

Ultragenyx Picks Andelyn Biosciences to Manufacture Novel Gene Therapy for Sanfilippo Syndrome

December 27, 2023

Andelyn Biosciences has been selected by Ultragenyx to manufacture UX111, that company’s gene therapy for treating Sanfilippo Syndrome.

NightHawk Biosciences Shifts into a Pure-Play Large-Molecule CDMO

December 20, 2023

Following the divestiture of its Elusys subsidiary and other non-core assets, NightHawk Biosciences will transform into a pure-play large-molecule CDMO.

Bristol Myers Squibb and SystImmune Enter Global ADC Collaboration Worth Potentially up to $8.4 Billion

December 19, 2023

Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.